The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancer

Trial ID #	Retrospective Study: Bevacizumab and Cyclophosphamide
Phase	II
Drug Class	Angiogenesis Inhibitors: VEGF
Drug Name	Bevacizumab
Alternate Drug Names	immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin
Drugs in Trial	Cyclophosphamide, Bevacizumab
Eligible Participant	Platinum resistant ovarian cancer
Patients Enrolled	66; median 6.5 prior therapies (3-16)
Therapy Setting	Recurrence
Study Design	Open-Label, Non-randomized
Endpoints	ORR, DCR, PFS, OS, evaluated per RECIST or CA125
Efficacy	ORR: 42.4% (7CR, 21PR, n=66) DCR: 65.1% (7CR, 21PR, 15SD, n=66) PFS: 3 months (0-14) OS: 12 months (2-56)
Clinically Significant Adverse Events	Serious AE: one bowel perforation Grade 3-4 AE: two patients with grade 4 hypertension with headache requiring presentation to the emergency room
Conclusion	Cyclophosphamide+bevacizumab is an effective, well-tolerated combination in heavily pretreated patients
Reference	Barber EL et al. The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancer. J Gynecol Oncol (2013) 24(3): 258-64 https://www.ncbi.nlm.nih.gov/pubmed/23875076